NCT04709263Completed
Heart Failure Patients Registry
Heart Failure Patients Registry A Prospective Observational Multicenter Registry of Patients With Chronic Heart Failure in the Population of the Russian Federation (PRIORITY-HF)
Source: ClinicalTrials.gov · Last updated 15 May 2025
Brief summary (registry, in English)
This study is a multicenter non-interventional observational prospective registry. This non-interventional study (NIS) does not imply any intervention into a routine clinical practice, including choice of treatment modality or special methods of investigation. The study will include only those patients who sign the informed consent form (ICF) after explanation of the study objectives and methods by the study physician. Planned study population consists of 20 000 adult outpatients with HF. All patients with HF who signed an ICF will be included to this study. Planned number of study sites is 150 outpatient centers in about 50 regions (in order to describe characteristics of outpatients with HF in different regions in the most comprehensive way). Expected inclusion period duration - 24 months OR reaching 20 000 patients, if this takes less than 24 months. Planned follow-up period duration for 1 patient is about 52 weeks (12 months), which includes 3 visits (visit 1 - inclusion; visit 2 - approximately 6 months after inclusion; visit 3 - approximately 12 months after inclusion)
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 19990 (actual)
- First submitted
- 22 Dec 2020
- Start date
- 21 Dec 2020
- Primary completion date
- 28 Mar 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Heart failure
- NCT number
- NCT04709263
What you commit to
- Study type: Observational
- Participants enrolled: 19990
- From 21 Dec 2020 to the primary completion date, 28 Mar 2024
- 65 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The participation in any randomised controlled trial within 3 months before the inclusion in this study or during the participation in this study.
Other
- The absence of signed ICF;
Who the study is looking for
- Age ≥ 18 years at the time of inclusion;
- Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study;
- Documented diagnosis of HF (according to Clinical Guidelines "Chronic Heart Failure", 2020, approved by MoH of RF) with typical symptoms/signs of HF consistent with I-IV functional classes of HF according to NYHA classification.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (65)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.